IDXX vs IQV
Idexx Laboratories and IQVIA, both Healthcare
Idexx Laboratories is the larger company at $44B against $28B. On trailing earnings IQV is the cheaper of the two at a P/E of 32.3 against 36.4, a gap that is only a bargain if the two are growing at similar rates. Over the past year IQV returned +37% against -21% for IDXX.
| Figure | IDXX | IQV |
|---|---|---|
| Last close | $518 | $260 |
| Market cap | $44B | $28B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 36.4 | 32.3 |
| 1-year return | -21% | +37% |
| 5-year return | -21% | +1.7% |
| RyuScoresector-relative, 1–10 | 70/100 | 70/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Idexx Laboratories
Revenue of $1.2B in Q2 2026, net income $338M. Its largest reported line is Vet Lab Consumables, 35% of the disclosed total.
IQVIA
Revenue of $4.2B in Q1 2026, net income $274M. Its largest reported line is Research And Development Solutions, 56% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.